This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Wednesday's Winners & Losers: Dendreon

Dendreon (DNDN) said that the FDA agreed to let it hasten clinical testing for its prostate cancer vaccine, Provenge. Dendreon still now expects final results from the trial in the second half of 2009 instead of 2010.

Shares jumped 46 cents, or 9.3%, to $5.39.

Shares of semiconductor equipment maker KLA-Tencor (KLAC - Get Report) fell $4.13, or 9.9%, to $37.80 after an Oppenheimer analyst cut his rating on the stock to underperform from perform.

The company is facing a decline in its market share and a "downward spiral" in one of its key product lines representing 10% to 15% of total revenue.

Boston Beer (SAM - Get Report), which makes beer in the Bay State's capital, climbed 26% to $45.16 after reporting fourth-quarter earnings shortly before the close Tuesday. Excluding items, the Samuel Adams brewer's earnings improved to $6.8 million, or 46 cents a share, from $2.5 million, or 17 cents a share, in the year-ago quarter. Analysts polled by Thomson Financial were expecting 35 cents a share.

Shares of hardwood flooring vendor Lumber Liquidators (LL - Get Report) also jumped, 15.5% to $8.81. The Toano, Va.-based company announced a year-over-year fourth-quarter profit increase of 71% to 12 cents a share, beating the consensus estimate by 2 cents. Revenue increased 24% year over year to $105.5 million. Lumber Liquidators also guided in line for 2008, forecasting EPS between 70 cents and 78 cents and revenue of $475 million to $490 million.

Shares of GPS-based navigation devices maker Garmin (GRMN - Get Report) added $2.59, or 4.6%, to $58.82 after a favorable article in Barron's Web site said the company's continued strong execution and its position as the market leader in the U.S. will work in its favor.

Elsewhere, Third Wave Technologies (TWTI) surged after the company said its test for high-risk HPV and an HPV genotyping test were successful in a clinical trial. Used with a Pap test, the company's HPV test checks for 14 strains of HPV. The genotyping product checks for HPV types 16 and 18, which cause 70% of cervical cancer cases.

The company, which said it would submit the results to the FDA in April, saw its shares soar $1.95, or 31.5%, to $9.34.

This article was written by a staff member of TheStreet.com.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
SYM TRADE IT LAST %CHG
TWTI $21.55 2.57%
DNDN $0.06 -6.02%
GRMN $45.16 -0.28%
KLAC $58.03 -0.79%
LL $27.05 -0.66%

Markets

DOW 17,774.99 -153.21 -0.85%
S&P 500 2,070.05 -19.41 -0.93%
NASDAQ 4,893.7140 -45.6130 -0.92%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs